Financial Ratios Neuronetics, Inc.
Equities
STIM
US64131A1051
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.315 USD | +1.15% |
|
-1.89% | -19.57% |
| Nov. 04 | Neuronetics, Inc., Q3 2025 Earnings Call, Nov 04, 2025 | |
| Nov. 04 | Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | -14.34 | -15.39 | -16.71 | -15.34 | -16.54 | ||||
Return on Total Capital | -17.56 | -17.94 | -19.47 | -18.45 | -20.11 | ||||
Return On Equity % | -74.86 | -56.37 | -52.25 | -66.17 | -132.53 | ||||
Return on Common Equity | -74.86 | -56.37 | -52.25 | -66.17 | -141.23 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 76.54 | 78.93 | 76.26 | 75.13 | 73.12 | ||||
SG&A Margin | 99.5 | 113.54 | 114.86 | 101.82 | 101.42 | ||||
EBITDA Margin % | -39.74 | -47.01 | -50.4 | -37.34 | -42.7 | ||||
EBITA Margin % | -41.65 | -48.93 | -52.93 | -40.02 | -45.35 | ||||
EBIT Margin % | -41.65 | -48.93 | -52.93 | -40.02 | -45.35 | ||||
Income From Continuing Operations Margin % | -55.75 | -56.39 | -56.99 | -42.31 | -58.39 | ||||
Net Income Margin % | -55.75 | -56.39 | -56.99 | -42.31 | -58.36 | ||||
Net Avail. For Common Margin % | -55.75 | -56.39 | -56.99 | -42.31 | -58.36 | ||||
Normalized Net Income Margin | -31.39 | -34.68 | -35.04 | -27.23 | -34.36 | ||||
Levered Free Cash Flow Margin | -34.8 | -29 | -30.86 | -28.38 | -23.52 | ||||
Unlevered Free Cash Flow Margin | -29.06 | -24.46 | -26.79 | -23.63 | -17.44 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.55 | 0.5 | 0.51 | 0.61 | 0.58 | ||||
Fixed Assets Turnover | 10.88 | 11.96 | 12.51 | 14.13 | 3.93 | ||||
Receivables Turnover (Average Receivables) | 5.97 | 5.84 | 5.21 | 4.49 | 3.72 | ||||
Inventory Turnover (Average Inventory) | 3.56 | 2.27 | 2 | 2.09 | 3.26 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 4.75 | 7.34 | 2.98 | 4.73 | 1.86 | ||||
Quick Ratio | 4.24 | 6.63 | 2.57 | 4 | 1.44 | ||||
Operating Cash Flow to Current Liabilities | -2.07 | -1.78 | -0.93 | -1.62 | -0.99 | ||||
Days Sales Outstanding (Average Receivables) | 61.32 | 62.55 | 70.06 | 81.38 | 98.35 | ||||
Days Outstanding Inventory (Average Inventory) | 102.87 | 161.04 | 182.25 | 174.78 | 112.2 | ||||
Average Days Payable Outstanding | 122.6 | 101.32 | 68.95 | 77.42 | 177.89 | ||||
Cash Conversion Cycle (Average Days) | 41.59 | 122.27 | 183.37 | 178.74 | 32.66 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 150.37 | 46.43 | 69.65 | 182.73 | 259.84 | ||||
Total Debt / Total Capital | 60.06 | 31.71 | 41.06 | 64.63 | 72.21 | ||||
LT Debt/Equity | 148.04 | 45.64 | 45.21 | 180.25 | 244.78 | ||||
Long-Term Debt / Total Capital | 59.13 | 31.17 | 26.65 | 63.76 | 68.02 | ||||
Total Liabilities / Total Assets | 67.59 | 39.69 | 51.18 | 70.48 | 77.43 | ||||
EBIT / Interest Expense | -4.54 | -6.73 | -8.12 | -5.26 | -4.66 | ||||
EBITDA / Interest Expense | -4.19 | -6.3 | -7.54 | -4.76 | -4.25 | ||||
(EBITDA - Capex) / Interest Expense | -4.36 | -6.88 | -8.31 | -5.2 | -4.45 | ||||
Total Debt / EBITDA | -2.02 | -1.56 | -1.24 | -2.42 | -2.67 | ||||
Net Debt / EBITDA | 0.56 | 2.16 | 0.95 | -0.11 | -2.07 | ||||
Total Debt / (EBITDA - Capex) | -1.95 | -1.43 | -1.12 | -2.21 | -2.55 | ||||
Net Debt / (EBITDA - Capex) | 0.54 | 1.97 | 0.87 | -0.1 | -1.98 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | -21.41 | 12.32 | 17.89 | 9.42 | 4.96 | ||||
Gross Profit, 1 Yr. Growth % | -20.26 | 15.84 | 13.89 | 7.81 | 2.16 | ||||
EBITDA, 1 Yr. Growth % | -24.35 | 32.89 | 26.38 | -20.63 | 19.6 | ||||
EBITA, 1 Yr. Growth % | -23.84 | 31.96 | 27.52 | -18.68 | 18.53 | ||||
EBIT, 1 Yr. Growth % | -23.84 | 31.96 | 27.52 | -18.68 | 18.53 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | -5.48 | 13.62 | 19.13 | -18.76 | 44.84 | ||||
Net Income, 1 Yr. Growth % | -5.48 | 13.62 | 19.13 | -18.76 | 44.78 | ||||
Normalized Net Income, 1 Yr. Growth % | -14.86 | 24.12 | 19.11 | -16.34 | 32 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | -7.76 | -16.01 | 12.83 | -23.74 | 30.75 | ||||
Accounts Receivable, 1 Yr. Growth % | 21.53 | 9.4 | 52.76 | 10.3 | 41.19 | ||||
Inventory, 1 Yr. Growth % | 34.05 | 76.42 | 35.59 | -9.06 | -47.51 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | -15.4 | 23.05 | 4.19 | -10.08 | 597.09 | ||||
Total Assets, 1 Yr. Growth % | -21.48 | 79.54 | -17.23 | -0.9 | 21.65 | ||||
Tangible Book Value, 1 Yr. Growth % | -47.93 | 250.62 | -35.34 | -43.9 | -136.46 | ||||
Common Equity, 1 Yr. Growth % | -46.73 | 234.11 | -33.01 | -40.08 | -18.96 | ||||
Cash From Operations, 1 Yr. Growth % | -6.86 | -1.43 | 9.85 | 4.23 | -3.25 | ||||
Capital Expenditures, 1 Yr. Growth % | -10.21 | 222.33 | 38.93 | -27.53 | -38.12 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | 7.27 | -6.4 | 25.45 | -1.21 | -13.3 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 4.67 | -5.47 | 29.1 | -5.5 | -22.84 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | -3.4 | -6.04 | 15.07 | 13.57 | 7.17 | ||||
Gross Profit, 2 Yr. CAGR % | -3.33 | -3.89 | 14.86 | 10.81 | 4.94 | ||||
EBITDA, 2 Yr. CAGR % | 1.61 | 0.27 | 24.01 | 0.16 | -2.39 | ||||
EBITA, 2 Yr. CAGR % | 1.69 | 0.25 | 24.38 | 1.78 | -1.65 | ||||
EBIT, 2 Yr. CAGR % | 1.69 | 0.25 | 24.38 | 1.78 | -1.65 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 6.74 | 3.63 | 16.34 | -1.62 | 8.48 | ||||
Net Income, 2 Yr. CAGR % | 6.74 | 3.63 | 16.34 | -1.62 | 8.45 | ||||
Normalized Net Income, 2 Yr. CAGR % | 1.3 | 2.8 | 17.39 | -0.17 | 5.26 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -26.43 | -11.98 | -2.65 | -7.24 | -0.15 | ||||
Accounts Receivable, 2 Yr. CAGR % | 26.92 | 15.31 | 29.27 | 29.8 | 24.79 | ||||
Inventory, 2 Yr. CAGR % | 23.68 | 53.79 | 54.67 | 11.05 | -30.91 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 73.5 | 2.03 | 13.23 | -3.21 | 150.37 | ||||
Total Assets, 2 Yr. CAGR % | -18.01 | 18.74 | 21.9 | -9.44 | 9.8 | ||||
Tangible Book Value, 2 Yr. CAGR % | -41.11 | 35.12 | 48.35 | -39.77 | -54.78 | ||||
Common Equity, 2 Yr. CAGR % | -40.1 | 33.42 | 49.61 | -36.64 | -30.32 | ||||
Cash From Operations, 2 Yr. CAGR % | 17.42 | -4.19 | 4.05 | 7 | 0.42 | ||||
Capital Expenditures, 2 Yr. CAGR % | -15.03 | 70.12 | 111.61 | 0.34 | -33.03 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | 12.44 | 0.2 | 4.97 | 11.28 | -7.31 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 12.79 | -0.53 | 6.37 | 10.37 | -14.45 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 6.79 | 1.58 | 1.34 | 13.16 | 10.63 | ||||
Gross Profit, 3 Yr. CAGR % | 6.96 | 2.68 | 1.7 | 12.46 | 7.84 | ||||
EBITDA, 3 Yr. CAGR % | 14.57 | 11.12 | 8.31 | 7.62 | 6.39 | ||||
EBITA, 3 Yr. CAGR % | 14.65 | 10.92 | 8.62 | 8.57 | 7.21 | ||||
EBIT, 3 Yr. CAGR % | 14.65 | 10.92 | 8.62 | 8.57 | 7.21 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 19.57 | 8.98 | 8.56 | 3.22 | 11.92 | ||||
Net Income, 3 Yr. CAGR % | 19.57 | 8.98 | 8.56 | 3.22 | 11.9 | ||||
Normalized Net Income, 3 Yr. CAGR % | 15.48 | 8.4 | 7.97 | 5.43 | 9.69 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -74.35 | -23.11 | -4.38 | -10.26 | 4 | ||||
Accounts Receivable, 3 Yr. CAGR % | 28.5 | 20.79 | 26.64 | 22.61 | 33.49 | ||||
Inventory, 3 Yr. CAGR % | 14.66 | 39.22 | 47.47 | 29.58 | -13.5 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 45.06 | 54.72 | 2.75 | 4.86 | 86.92 | ||||
Total Assets, 3 Yr. CAGR % | 26.41 | 6.47 | 5.28 | 13.77 | -0.08 | ||||
Tangible Book Value, 3 Yr. CAGR % | -49.89 | 6.74 | 4.65 | 7.28 | -49.05 | ||||
Common Equity, 3 Yr. CAGR % | -49.04 | 6.23 | 6.04 | 10.28 | -31.23 | ||||
Cash From Operations, 3 Yr. CAGR % | 36.58 | 10.77 | 0.28 | 4.11 | 3.47 | ||||
Capital Expenditures, 3 Yr. CAGR % | 7.11 | 32.52 | 59.02 | 48.05 | -14.59 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 25.87 | 5.78 | 8 | 3.5 | 2.5 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 27.91 | 6.34 | 8.5 | 2.99 | -1.92 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 10.07 | 10.03 | 6.22 | 3.63 | ||||
Gross Profit, 5 Yr. CAGR % | - | 9.6 | 10.05 | 5.86 | 2.99 | ||||
EBITDA, 5 Yr. CAGR % | - | 24.58 | 20.36 | 7.05 | 4.34 | ||||
EBITA, 5 Yr. CAGR % | - | 23.72 | 20.46 | 7.56 | 4.75 | ||||
EBIT, 5 Yr. CAGR % | - | 23.72 | 20.46 | 7.56 | 4.75 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 22.66 | 18.27 | 4.61 | 8.53 | ||||
Net Income, 5 Yr. CAGR % | - | 22.66 | 18.27 | 4.61 | 8.52 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 22.26 | 17.88 | 5.23 | 7.23 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | -56.31 | -56.27 | -17.12 | -2.71 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 22.59 | 28.81 | 24.32 | 25.9 | ||||
Inventory, 5 Yr. CAGR % | - | 31.08 | 29.24 | 27.18 | 8.89 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 25.68 | 31.37 | 28.25 | 46.72 | ||||
Total Assets, 5 Yr. CAGR % | - | 41.61 | 24.59 | -0.2 | 7.06 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | -13.62 | -22.65 | -15.6 | -25.19 | ||||
Common Equity, 5 Yr. CAGR % | - | -13.62 | -21.6 | -13.61 | -10.35 | ||||
Cash From Operations, 5 Yr. CAGR % | - | 26.79 | 22.5 | 9.24 | 0.34 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 48.67 | 40.65 | 18.57 | 12.51 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 18.55 | 8.36 | 1.97 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 20.63 | 8.43 | -0.92 |
- Stock Market
- Equities
- STIM Stock
- Financials Neuronetics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















